Is Moderna Stock a Buy After Plunging More Than 35%?
Throughout most of 2020 and 2021, it seemed as if Moderna (NASDAQ: MRNA) could do no wrong. The company won multiple supply deals for its COVID-19 vaccine. Moderna's revenue and profits skyrocketed. And so did its share price.
The last couple of months have been much different. There's been plenty of bad news for Moderna. Most of the summer's gains have evaporated. However, this major pullback has prompted some investors to wonder if the vaccine stock has fallen more than is warranted. Is Moderna stock a buy after plunging more than 35%?
Image source: Getty Images.
Source Fool.com
